IRRAS is Bringing Needed Innovation to Neurocritical Care with Will Martin Leading the Way as Incoming CEO
Will Martin's promotion comes as part of a planned succession process that was first announced in April 2021. Kleanthis G. Xanthopoulos, Ph.D., the company’s CEO for the previous 6 years, will remain on the Company’s Board of Directors.
The collaboration with Aarhus University's neurosurgical team will evaluate IRRAflow during the treatment of Intraventricular Hemorrhage (IVH) and assessment of brain compliance
The initial area of focus will be in the treatment of patients suffering from intraventricular hemorrhage (IVH).
"We finally received the feedback from G-MED on the IRRAflow after a lengthy period," said Kleanthis G. Xanthopoulos, Ph.D, President and CEO of IRRAS.